Estudio observacional sobre tratamiento trombolítico del infarto cerebral agudo en pacientes mayores y menores de 80 años: experiencia de un hospital en Bogotá, Colombia, 2007-2014
| dc.contributor.author | Hernán Bayona | |
| dc.contributor.author | Camilo Andrés Díaz-Cruz | |
| dc.contributor.author | Lina Góez-Mogollón | |
| dc.contributor.author | Nicolás Useche-Gómez | |
| dc.contributor.author | María Camila Valencia-Mendoza | |
| dc.contributor.author | Valerie Jeanneret López | |
| dc.contributor.author | Andrés Díaz-Campos | |
| dc.contributor.author | María Camila Valencia-Mendoza | |
| dc.contributor.author | Universidad de los Andes | |
| dc.contributor.author | Valerie Jeanneret López | |
| dc.coverage.spatial | Bolivia | |
| dc.date.accessioned | 2026-03-22T15:16:12Z | |
| dc.date.available | 2026-03-22T15:16:12Z | |
| dc.date.issued | 2017 | |
| dc.description | Citaciones: 3 | |
| dc.description.abstract | Background: we depict the experience with the use of thrombolysis for acute ischemic stroke in a tertiary center in South America. Objective: to describe the main outcomes in our population of patients aged less and older than 80 years treated with recombinant tissue plasminogen activator. Materials and Methods: retrospective observational study. We described the main variables and the difference in outcome accounting for age. Results: 70 patients were included. 51.4% of the patients were women, 22.8% were older than 80 years. The average window time was 70 minutes and the average door-to-needle time was 90 minutes. Hypertension, dyslipidemia and previous stroke were the most common risk factors. Favorable outcome Modified Rankin Scale 2 was present in 25% of the patients older than 80 years and 53.7% in the population younger than 80 years (p=0.009). Mortality was present in 31.2% of the patients older than 80 years and in 5.5% of the patients younger than 80 years (p=0.005). Symptomatic intra-cerebral hemorrhage was found in 6.25% of the patients older than 80 years (p=0.65), compared to 3.7% in the younger than 80 years. Conclusions: we found that intravenous thrombolysis still had benefit in people older than 80 years. Significant differences in symptomatic intra-cerebral hemorrhage were not found, however, a greater mortality in patients older than 80 years was. These findings of our experience of recombinant tissue plasminogen activator use in real life are consistent with other latinamerican publications. MD.UIS. | |
| dc.identifier.doi | 10.18273/revmed.v30n3-2017002 | |
| dc.identifier.uri | https://doi.org/10.18273/revmed.v30n3-2017002 | |
| dc.identifier.uri | https://andeanlibrary.org/handle/123456789/51381 | |
| dc.language.iso | es | |
| dc.relation.ispartof | Revista Médicas UIS | |
| dc.source | Universidad de Los Andes | |
| dc.subject | Medicine | |
| dc.subject | Humanities | |
| dc.title | Estudio observacional sobre tratamiento trombolítico del infarto cerebral agudo en pacientes mayores y menores de 80 años: experiencia de un hospital en Bogotá, Colombia, 2007-2014 | |
| dc.type | article |